| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.05 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.087 | 0.06 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.06 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.058 | 0.06 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.087 | 0.06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.05 | 0.07 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.07 |